Innogenetics announces definitive closure of GENimmune
Advertisement
Innogenetics announced the final phase of its restructuring plan for the pharma division of GENimmune. In accordance with the collective labor agreement signed on May 8 with its social partners, the remaining 5 labor contracts will shortly be terminated.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
IXICO and PsiOxus Therapeutics win significant funding from government-backed Biomedical Catalyst
New CEO at the GUS Group - Thorsten Schlechtriem takes the helm
Integragen becomes first certified French service provider for Illumina GoldenGate and Infinium genotyping
Global Fairs - Paris, France